Non-alcoholic fatty liver disease: pathogenesis and models

Zhong, Hanxiang

doi:10.62347/kmsa5983

Cited by 37Liver Disease Diagnosis and TreatmentLiver physiology and pathologyDiet, Metabolism, and Disease

Non-alcoholic fatty liver disease: pathogenesis and models

Open access

Zhong, Hanxiang·2024·American Journal of Translational Research

DOI 10.62347/kmsa5983PMC PMC10918142

Open this paper in CoChat — free account

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a complex disease characterized by a massive accumulation of lipids in the liver, with a continuous progression of simple steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Non-alcoholic fatty liver disease is associated with obesity, insulin resistance, and metabolic syndrome; it is a severe public health risk and is currently the most common liver disease of the world. In addition to the fatty infiltration of the liver in non-alcoholic fatty liver disease patients, the field of liver transplantation faces similar obstacles. NAFLD and NASH primarily involve lipotoxicity, inflammation, oxidative stress, and insulin resistance. However, the precise mechanisms and treatments remain unclear. Therapeutic approaches encompass exercise, weight control, as well as treatments targeting antioxidants and anti-inflammatory pathways. The role of animal models in research has become crucial as a key tool to explore the molecular mechanisms and potential treatments for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Here, we summarized the current understanding of the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis and discussed animal models commonly used in recent years.

Integrity signals

Registry

Crossref · 10.62347/kmsa5983

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Induction of MASLD in vitro using FFAs leads to pronounced and quantitatively measurable lipid accumulation in cell lines within 24-72 h, contrasting with animal models where HFD induces steatosis in 8-16 weeks, steatohepatitis in 16-36 weeks, and fibrosis/cirrhosis in 24-52 weeks or more.
“Induction of MASLD in vitro using free fatty acids leads to a pronounced and quantitatively measurable accumulation of lipids in cell lines within 24–72 h [29].”
From The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease (2026) · cites this paper as [57]

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · see citing works
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · see citing works
Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844 · see citing works
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · see citing works
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature reviews. Immunology · doi:10.1038/nri1937 · Cited by 3,195 · see citing works
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119 · see citing works
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · see citing works
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,416 · see citing works
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,413 · see citing works
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · see citing works
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245 · see citing works
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxı̀, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,986 · see citing works
Insulin Receptor Signaling in Normal and Insulin-Resistant StatesPreprint
Boucher, J., Kleinridders, A., & Kahn, C. R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009191 · Cited by 1,473 · see citing works
AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome
Zhang, B. B., Zhou, G., & Li, C. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.012 · Cited by 1,028 · see citing works
Fructose consumption as a risk factor for non-alcoholic fatty liver disease
Ouyang, X., Cirillo, P., Sautin, Y. Y., McCall, S. J., Bruchette, J. L., Diehl, A. M., Johnson, R. J., & Abdelmalek, M. F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.02.011 · Cited by 862 · see citing works
Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver Disease
Abdelmalek, M. F., Suzuki, A., Guy, C. D., Ünalp–Arida, A., Colvin, R., Johnson, R. J., & Diehl, A. M. (2010) · Hepatology · doi:10.1002/hep.23535 · Cited by 767 · see citing works
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J., & Newsome, P. N. (2009) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 742 · see citing works
Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research
Anstee, Q. M., & Goldin, R. D. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2006.00465.x · Cited by 714 · see citing works
Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis
Marı́, M., Caballero, F. G., Colell, A., Morales, A., Caballería, J., Fernandez, A., Enrich, C., Fernández-Checa, J. C., & García‐Ruiz, C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.07.006 · Cited by 605 · see citing works
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554 · see citing works
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 529 · see citing works
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 522 · see citing works
Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet
Matsuzawa, N., Takamura, T., Kurita, S., Misu, H., Ota, T., Ando, H., Yokoyama, M., Honda, M., Zen, Y., Nakanuma, Y., et al. (2007) · Hepatology · doi:10.1002/hep.21874 · Cited by 516 · see citing works
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression
Corbin, K. D., & Zeisel, S. H. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834e7b4b · Cited by 502 · see citing works
Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss
Gregor, M. F., Yang, L., Fabbrini, E., Mohammed, B. S., Eagon, J. C., Hotamisligil, G. S., & Klein, S. (2009) · Diabetes · doi:10.2337/db08-1220 · Cited by 488 · see citing works
Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin
Kamada, Y., Tamura, S., Kiso, S., Matsumoto, H., Saji, Y., Yoshida, Y., Fukui, K., Maeda, N., Nishizawa, H., Nagaretani, H., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.029 · Cited by 480 · see citing works
Insulin resistance associated to obesity: the link TNF-alpha
Nieto-Vázquez, I., Fernández‐Veledo, S., Kramer, D., Vila‐Bedmar, R., García‐Guerra, L., & Lorenzo, M. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802181047 · Cited by 475 · see citing works
Histopathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i42.5286 · Cited by 448 · see citing works
Insulin Resistance in Nonalcoholic Fatty Liver Disease
Bugianesi, E., Moscatiello, S., Ciaravella, M. F., & Marchesini, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208875 · Cited by 446 · see citing works
Model of nonalcoholic steatohepatitis
Lieber, C. S., Leo, M. A., Mak, K. M., Xu, Y., Cao, Q., Ren, C., Ponomarenko, A. N., & DeCarli, L. M. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.3.502 · Cited by 425 · see citing works
Leptin is essential for the hepatic fibrogenic response to chronic liver injury
Leclercq, I. A., Farrell, G. C., Schriemer, R., & Robertson, G. R. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00102-2 · Cited by 407 · see citing works
Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients
Ribeiro, P. S., Cortez‐Pinto, H., Solá, S., Castro, R. E., Ramalho, R. M., Baptista, A., de Moura, M. C., Camilo, M., & Rodrigues, C. M. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40009.x · Cited by 392 · see citing works
Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease
Machado, M. V., Michelotti, G. A., Xie, G., Pereira, T. A., Boursier, J., Bohnic, B., Guy, C. D., & Diehl, A. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127991 · Cited by 381 · see citing works
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312 · see citing works
Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle
Park, S. H., Gammon, S. R., Knippers, J. D., Paulsen, S. R., Rubink, D. S., & Winder, W. W. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00071.2002 · Cited by 310 · see citing works
Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis
Savard, C. E., Tartaglione, E. V., Kuver, R., Haigh, G. W., Farrell, G. C., Subramanian, S., Chait, A., Yeh, M. M., Quinn, L. S., & Ioannou, G. N. (2012) · Hepatology · doi:10.1002/hep.25789 · Cited by 297 · see citing works
Obese and diabetic <i>db</i>/<i>db</i> mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin
Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R. M., & Whitington, P. F. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00199.2004 · Cited by 290 · see citing works
The lysosomal-mitochondrial axis in free fatty acid–induced hepatic lipotoxicity
Li, Z.-Z., Berk, M. P., McIntyre, T. M., Gores, G. J., & Feldstein, A. E. (2008) · Hepatology · doi:10.1002/hep.22183 · Cited by 289 · see citing works
Fatty acid—induced inflammation and insulin resistance in skeletal muscle and liver
Boden, G. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0031-x · Cited by 276 · see citing works
Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin
Suriano, F., Vieira‐Silva, S., Falony, G., Roumain, M., Paquot, A., Pelicaen, R., Régnier, M., Delzenne, N. M., Raes, J., Muccioli, G. G., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01097-8 · Cited by 270 · see citing works
Adiponectin, a key adipokine in obesity related liver diseases.
Buechler, C., Wanninger, J., & Neumeier, M. (2011) · PubMed Central · doi:10.3748/wjg.v17.i23.2801 · Cited by 261 · see citing works
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets
Kakuma, T., Lee, Y., Higa, M., Wang, Z.-W., Pan, W., Shimomura, I., & Unger, R. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8536 · Cited by 261 · see citing works
Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis
George, J., Pera, N., Phung, N., Leclercq, I. A., Hou, J. Y., & Farrell, G. C. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00376-3 · Cited by 247 · see citing works
Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions
Adolph, T. E., Grander, C., Grabherr, F., & Tilg, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081649 · Cited by 243 · see citing works
Subcellular Localization of ALMS1 Supports Involvement of Centrosome and Basal Body Dysfunction in the Pathogenesis of Obesity, Insulin Resistance, and Type 2 Diabetes
Hearn, T., Spalluto, C. M., Phillips, V., Renforth, G. L., Copin, N., Hanley, N. A., & Wilson, D. I. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1581 · Cited by 235 · see citing works
Fructose as a key player in the development of fatty liver disease
Basaranoglu, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i8.1166 · Cited by 235 · see citing works
Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis
Medina, J., Fernández-Salazar, L. I., García-Buey, L., & Moreno‐Otero, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2057 · Cited by 229 · see citing works
The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease
Nomura, K., & Yamanouchi, T. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.09.006 · Cited by 213 · see citing works
Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment
Schreuder, T. C. M. A., Verwer, B. J., van Nieuwkerk, C. M., & Mulder, C. J. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2474 · Cited by 189 · see citing works
Nonalcoholic fatty liver disease in type 2 diabetes mellitus
Cusi, K. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283293015 · Cited by 185 · see citing works
High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate–activated protein kinase
Adachi, M., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.21991 · Cited by 182 · see citing works
The Evolving Role of Leptin and Adiponectin in Chronic Liver Diseases
Tsochatzis, E. A., Papatheodoridis, G., & Archimandritis, A. J. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00848.x · Cited by 182 · see citing works
Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease
Targher, G., Bertolini, L., Rodella, S., Zoppini, G., Scala, L., Zenari, L., & Falezza, G. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02527.x · Cited by 172 · see citing works
Fat Aussie—A New Alström Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and Spermatogenesis
Arsov, T., Silva, D. G., O’Bryan, M. K., Sainsbury, A., Lee, N. J., Kennedy, C., Manji, S. S. M., Nelms, K., Liu, C., Vinuesa, C. G., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0494 · Cited by 166 · see citing works
Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk
Athyros, V. G., Boutari, C., Stavropoulos, K., Anagnostis, P. G., Imprialos, K. P., Doumas, M. N., & Karagiannis, A. I. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161115666170621082910 · Cited by 160 · see citing works
Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet
Trak-Smayra, V. E., Paradis, V., Massart, J., Nasser, S. M., Jebara, V. A., & Fromenty, B. (2011) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2011.00793.x · Cited by 147 · see citing works
MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes
Larter, C. Z., Yeh, M. M., Williams, J., Bell-Anderson, K. S., & Farrell, G. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.026 · Cited by 133 · see citing works
Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation
Grattagliano, I., de Bari, O., Bernardo, T. C., Oliveira, P. J., Wang, D. Q. ‐., & Portincasa, P. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.024 · Cited by 128 · see citing works
Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy
Paz-Filho, G., Mastronardi, C. A., Delibaşı, T., Wong, M., & Licinio, J. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000800005 · Cited by 104 · see citing works
Pro-Inflammatory CXCR3 Impairs Mitochondrial Function in Experimental Non-Alcoholic Steatohepatitis
Du, J., Zhang, X., Han, J., Man, K., Zhang, Y., Chu, E. S., Nan, Y., & Yu, J. Q. (2017) · Theranostics · doi:10.7150/thno.21400 · Cited by 92 · see citing works
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
(2018) · Clinical Liver Disease · doi:10.1002/cld.722 · Cited by 85 · see citing works
Strain dependence of diet‐induced <scp>NASH</scp> and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype
Farrell, G. C., Mridha, A. R., Yeh, M. M., Arsov, T., Van Rooyen, D. M., Brooling, J., Nguyen, T., Heydet, D., Delghingaro‐Augusto, V., Nolan, C. J., et al. (2014) · Liver International · doi:10.1111/liv.12335 · Cited by 85 · see citing works
Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice
Yamamoto, T. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2512 · Cited by 48 · see citing works
MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM
Tian, C., Min, X., Zhao, Y., Wang, Y., Wu, X., Liu, S., Dou, W., Zhou, T., Liu, Y., Luo, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.017 · Cited by 47 · see citing works
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model
Briand, F., Brousseau, E., Quinsat, M., Burcelin, R., & Sulpice, T. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.11.021 · Cited by 41 · see citing works
Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets
Fakhoury-Sayegh, N., Trak-Smayra, V. E., Khazzaka, A., Esseily, F., Obeid, O., Lahoud-Zouein, M., & Younes, H. (2015) · Nutrition Research and Practice · doi:10.4162/nrp.2015.9.4.350 · Cited by 39 · see citing works
Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse
Riordan, J. D., & Nadeau, J. H. (2014) · Mammalian Genome · doi:10.1007/s00335-014-9521-3 · Cited by 36 · see citing works
Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice
Yamada, T., Obata, A., Kashiwagi, Y., Rokugawa, T., Matsushima, S., Hamada, T., Watabe, H., & Abe, K. (2016) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2016.03.009 · Cited by 35 · see citing works
Proteomic Analysis of Mice Fed Methionine and Choline Deficient Diet Reveals Marker Proteins Associated with Steatohepatitis
Lee, S. J., Kang, J. H., Iqbal, W., & Kwon, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120577 · Cited by 33 · see citing works
Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH
Vargas-Pozada, E. E., Ramos‐Tovar, E., Rodríguez-Callejas, J. D., Cardoso-Lezama, I., Galindo‐Gómez, S., Gil-Becerril, K. M., Vásquez-Garzón, V. R., Arellanes‐Robledo, J., Tsutsumi, V., Villa‐Treviño, S., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100780 · Cited by 15 · see citing works
Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer.
Lau, J., Zhang, X., & Yu, J. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_11 · Cited by 14 · see citing works

Flagged first, then by citations

Sorted by citations

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., & Singh, B. K. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1433857 · Cited by 229 · see citing works
GPR41 and GPR43: From development to metabolic regulation
Lee, D., Kim, M.-T., & Han, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116735 · Cited by 160 · see citing works
Caffeic acid ameliorates metabolic dysfunction-associated steatotic liver disease via alleviating oxidative damage and lipid accumulation in hepatocytes through activating Nrf2 via targeting Keap1
Zhang, J., Ouyang, H., Gu, X.-N., Dong, S., Lu, B., Huang, Z., Li, J., & Ji, L. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.08.038 · Cited by 58 · see citing works
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
Sergi, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158462 · Cited by 43 · see citing works
Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy
Xia, M., Varmazyad, M., Plá-Palacín, I., Gavlock, D. C., DeBiasio, R., LaRocca, G. M., Reese, C. E., Florentino, R. M., Faccioli, L. A. P., Brown, J. A., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1423936 · Cited by 21 · see citing works
Exosomes derived from apical papilla stem cells improve NASH by regulating fatty acid metabolism and reducing inflammation
Nie, Y.-F., Meng, W., Liu, D., Yang, Z., Wang, W., Ren, H., Mao, K., Lan, W., Li, C., Wang, Z., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00945-1 · Cited by 17 · see citing works
Glucose Variability in People with Type 1 Diabetes: Associations with Body Weight, Body Composition, and Insulin Sensitivity
Semenova, J. F., Yushin, A. Y., Korbut, A. I., & Klimontov, V. V. (2024) · Biomedicines · doi:10.3390/biomedicines12092006 · Cited by 10 · see citing works
Association Between Whole Blood Iron and Nonalcoholic Fatty Liver Disease in Elderly: A Case–Control Study
Jiang, Z., Meng, W.-J., Wang, Y., Su, H.-Q., Mao, B.-X., Wang, C.-L., Peng, F.-L., Li, C., & He, L. (2025) · Biological Trace Element Research · doi:10.1007/s12011-025-04846-0 · Cited by 10 · see citing works
Association of cardiometabolic markers with hepatic steatosis and liver fibrosis in population without obesity and diabetes
Fan, Z., Yang, C., Zhao, X., & Zhang, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-01003-4 · Cited by 9 · see citing works
Molecular insights into physiological impact of micro- and nano-plastics on the digestive system and gut-brain axis
Yuvika, Sharma, D., & Sharma, A. (2026) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2026.110473 · Cited by 9 · see citing works
Empagliflozin Attenuates Liver Inflammation and Fibrosis in NAFLD: Evidence from Mendelian Randomization and Mouse Experiments
Fu, C., Deng, L., Zhu, X., Wang, B., Hu, B., Xue, H., Zeng, Q., & Zhang, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100846 · Cited by 7 · see citing works
Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review
Yeh, H., Lin, S. J., Shen, H., Li, T., Tsai, H., Yang, Y., Lin, H.-C., & Hou, M. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001254 · Cited by 6 · see citing works
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026) · International journal of molecular sciences · doi:10.3390/ijms27083399 · Cited by 5 · see citing works
Relationship between albumin-corrected anion gap and non-alcoholic fatty liver disease: a cross-sectional analysis of NHANES 2017–2018
Bai, N., Ying, T., Li, D., & Liu, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1518540 · Cited by 5 · see citing works
Non-Alcoholic Fatty Liver Disease in Everyday Clinical Practice: From Diagnosis to Therapy
Kosmalski, M., & Mokros, Ł. (2025) · Life · doi:10.3390/life15030363 · Cited by 4 · see citing works
Hypoxia-inducible factors in the immunometabolism of metabolic dysfunction-associated steatotic liver disease (MASLD): molecular mechanisms and therapeutic implications
Zhao, Y., Wang, Y., Li, F., & Yu, G. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1779019 · Cited by 3 · see citing works
Analysis of Health-Related Quality of Life and Its Influencing Factors Among Patients with Non-Alcoholic Fatty Liver Disease in Hangzhou, China: A Cross-Sectional Study
Fei, H., Lv, K., Xu, J., Hao, H., Quan, Y., Shi, J., & Zhang, W. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251363914 · Cited by 2 · see citing works
Hyperoside ameliorates NAFLD in rats via remodeling gut microbiota and reprogramming serum metabolic networks
Huang, M., Wang, Y., Li, Y., & Zeng, W. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1741026 · Cited by 2 · see citing works
The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study
Song, L., Zhang, L., Hang, Y., Yang, Z., Yang, J., & Wang, D. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1788704 · Cited by 2 · see citing works
Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum : A potential antiobesity strategy
Citriniti, E. L., Rocca, R., Costa, G., Renzi, G., Carta, F., Supuran, C. T., Alcaro, S., & Ortuso, F. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400966 · Cited by 2 · see citing works
Nutrition: A Cornerstone for Child Growth and Development in Addressing the Triple Burden of Malnutrition
Kaur, R., Goel, V., Kanotra, M., Choudhary, D., & Singh, T. G. (2025) · Springer eBooks · doi:10.1007/978-981-95-2994-0_13 · Cited by 1 · see citing works
3D bioprinted connections in Liver‒Pancreas crosstalk: Lessons learned and future directions
Murucci, M. D., Onikanni, S. A., Goldstein, A. D. C., Aribigbola, T. C., Xavier, C. D. C., Olayinka, O. S., Dezonne, R. S., Pereira, L. D. C. B., Bonfim, D. C., Miranda‐Alves, L., et al. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112806 · Cited by 1 · see citing works
Advances in mesenchymal stem cell therapy and natural antioxidants for hepatic fibrosis: A comprehensive review
Kazmi, A., & Sultana, T. (2024) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2024.100016 · Cited by 1 · see citing works
Association Between Sleep Quality and Cirrhotic Cardiomyopathy: A Prospective Case-Control Study
Liu, F., Cao, T., Liu, Y., Huang, D., & Zhang, J. (2024) · Nature and Science of Sleep · doi:10.2147/nss.s482592
КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
Фофанова, О. Ю., Феденько, В. В., Гурик, З., Кіндратів, Е. О., & Лаб'як, І. Г. (2025) · Art of Medicine · doi:10.21802/artm.2025.2.34.113
Regulatory Role of Nuclear Factor of Activated T Cells c4 in the Development of Metabolic dysfunction-associated Fatty Liver Disease
Shen, T., Chen, J., Li, L., Li, G., Guo, Q., Liang, M., & Pang, Q. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01374-z
Polysaccharides from the Cherry Peel of Coffea arabica L. Attenuate Obesity by Altering Lipid Metabolism and Inflammation and Regulating Gut Microbiota in Mice Fed a High-Fat Diet
Hu, G., Gu, Y., Zhang, W., He, X., Wu, X.-Z., Jiang, Y., Li, H., & Cao, Y. C. (2026) · Foods · doi:10.3390/foods15020312
Pycnogenol mitigates obesity-associated liver injury via Nrf2/HO-1 activation and NF-κB restraint in rats
Yakut, S., Ulaş, N., & İmik, A. (2026) · Veteriner Hekimler Derneği Dergisi · doi:10.33188/vetheder.1790255
Suppression of non-alcoholic fatty liver disease by thymoquinone associated with inhibition of miRNA-155/ROS/p53/TIMP-1-mediated fibrosis and autophagy upregulation
Alshahrani, M. Y., Amri, F. S. A., Bayoumy, N. M. K., Suliman, M., Aboulhoda, B. E., Abdallah, H. A., Ibrahim, W., Elwi, H. M., Albawardi, A. S., Al‐Ani, B., et al. (2026) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2025-0102
Hepatoprotection by Garlic Essential Oil Nanoemulsion Through Nrf2‐Mediated Antioxidant Response and Inhibition of TLR4 / NF ‐ κB / NLRP3 Axis in High‐Fat Diet‐Fed Rats
Alfawaz, M. S., Doghaither, H. A. A., Al-Ghafari, A. B., Mansour, A. A., Alshammari, A. N., Elmorsy, E. M., Atta, M. G., & Megahed, A. (2026) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.70115
Menopause Transition: The Interaction Between Weight Gain, Cardiovascular Disease Risk, and Lifestyle
Rivera, R., Castaneda, R., Sobel, T., & Andrade, M. D. H. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_8
Integrative Functional Nutrition in Metabolic-Associated Fatty Liver Disease
Güveli, H. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016113
Comparative Analysis of Classical and Emerging Experimental Animal Models of Liver Injury: A Comprehensive Review
Salman, I. N., Jabbar, R. K., Emad, I., Hassan, Z. A. A., Harbi, A. M., Khudhair, A. Y., Hussein, M. A. M., Hamid, A. M., Amir, M. A. A., Ali, M. W., et al. (2026) · Journal of Applied Toxicology · doi:10.1002/jat.70268
HEPATIC INVOLVEMENT IN RHEUMATOID ARTHRITIS: CAUSES, COMORBIDITIES, AND CLINICAL IMPLICATIONS
Sękulski, M., Mrozek, M., Zydlewski, I., Blecharczyk, M., Pacanowska-Trawnicka, M., & Jakubiec, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5426
Preparation and Hypoglycemic Activity of Enzymatically Hydrolyzed Peptides From the Swim Bladder of Pangasius bocourti
Yang, J., Qiu, X., Zhang, H., Wu, K., Li, Y., Xu, G., He, J., Chen, J., & Tang, X. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72061
Association of Circulating Paraoxonase 3 and GDF-15 levels with hepatic lipid metabolism disorder in MAFLD patients
Qian, X., Wang, Y., Zhu, H., 华先志, Wang, L., Fang, P., & Xu, Y. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121293
Lactobacillus rhamnosus Lysate for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial
Savytska, M., Ilkiv, Y., Baka, O., Манжалій, Е., Yerokhovych, V., Kyriienko, D., Falalyeyeva, T., Petakh, P., Halabitska, I., Kamyshnyi, O., et al. (2026) · Medicina · doi:10.3390/medicina62101893

Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
Basha, A., May, S. C., Anderson, R. M., Samala, N. R., & Mirmira, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129996 · Cited by 14 · see citing works
Pathogenesis of and major animal models used for nonalcoholic fatty liver disease
Jiang, M., Wu, N., Chen, X., Wang, W., Chu, Y., Liu, H., Li, W., Chen, D., Li, X., & Xu, B. (2019) · Journal of International Medical Research · doi:10.1177/0300060519833527 · Cited by 36 · see citing works
Non-alcoholic Fatty Liver Disease: Pathology, Disease Models and Therapies
Wu, Z. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5702
Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
Berardo, C., Pasqua, L. G. D., Cagna, M., Richelmi, P., Vairetti, M., & Ferrigno, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249646 · Cited by 80 · see citing works
Research advances in animal models based on the pathogenesis and treatment of nonalcoholic fatty liver disease
Yanzhen, C. (2017) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/j.issn.1001-5256.2017.12.046

Authors: Zhong, H.
Affiliations: Second Military Medical University (CN)
Corresponding author: Zhong, Hanxiang
Venue: American Journal of Translational Research
Publisher: e-Century Publishing Corporation
Published: 2024
Volume: 16
Issue: 2
Pages: 387-399
ISSN: 1943-8141 (ISSN-L)
DOI: 10.62347/kmsa5983
PMC: PMC10918142
OpenAlex: W4393045538
Cited by: 37
References: 73
Citations by year: 2026: 17 · 2025: 11 · 2024: 9
FWCI: 11.29
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: American Journal of Translational Research (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords: non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, pathogenesis, animal models, hepatic steatosis, insulin resistance, metabolic syndrome, obesity, lipotoxicity, oxidative stress, liver inflammation, hepatocellular carcinoma, liver cirrhosis, antioxidants, anti-inflammatory therapy, physical activity, weight management, liver transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Non-alcoholic fatty liver disease: pathogenesis and models

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks